An Oxfordshire university student is among those set to receive a "transformative" gene-therapy treatment on the NHS for sickle ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

A revolutionary gene therapy treatment costing a staggering £1.65 million has been approved for NHS use, offering patients ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain patients with severe sickle cell disease. Here patients have reacted to the ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

In the ever-evolving digital world, selling feet pictures online has become an unconventional yet profitable business, with sites like Instafeet experiencing a user growth of 50% in 2021 alone, making ...

What’s more, some analysts suggest there is a ready-made buyer in CRISPR’s partner on Casgevy, Vertex Pharmaceuticals. Now Vertex is a massive company with a market cap of $106bn and more than ...